Glimilife M2 Forte Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 1000mg, formulated to manage type 2 diabetes mellitus effectively. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting consistent plasma drug levels and reducing gastrointestinal side effects commonly associated with metformin. Glimilife M2 Forte is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. It is essential to use this medication under medical supervision, with regular monitoring of blood glucose and renal function, as metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and, rarely, lactic acidosis. Dose adjustments may be necessary based on therapeutic response and tolerability. This combination therapy offers a synergistic approach to managing hyperglycemia, improving patient compliance through reduced pill burden and sustained glycemic control.